Intellia Therapeutics, Inc.
NTLA Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$11.26
KIRA · Stoqly’s AI analyst, in plain words
- Intellia Therapeutics, Inc. had $67.7M of revenue in fiscal 2025, up 16.9% on the year before. Over five years, revenue changed +3.1% a year on average.
- Its operating margin was −651.7%, up 271.4 pts: of every 100 in sales, about −652 is left after running the business.
- Intellia Therapeutics, Inc. lost $413M in fiscal 2025.
- Free cash flow was −$396M in fiscal 2025, −585.0% of revenue.
Market cap
$1.5B
P/E
—
Revenue
$67.7M
Net income
−$413M
Free cash flow
−$396M
Operating margin
−651.7%
Intellia Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+16.9%
Yes. Sales grew 16.9% last year.
Does it make a profit?
−609.9%
No. It lost money last year.
Does profit turn into cash?
−585.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Intellia Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Intellia Therapeutics, Inc.
- CIK
- 0001652130
Intellia Therapeutics, Inc. · NTLA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Revenue growth | −43.0% | 57.7% | −30.4% | 59.6% | 16.9% |
| Gross margin | 100.0% | — | — | — | — |
| Operating margin | −810.4% | −879.0% | −1,420.5% | −923.1% | −651.7% |
| Net income | −$268M | −$474M | −$481M | −$519M | −$413M |
| Net margin | −810.5% | −909.8% | −1,326.5% | −896.8% | −609.9% |
| Diluted EPS | −$3.78 | −$6.16 | −$5.42 | −$5.25 | −$3.81 |
| Cash | |||||
| Cash from operations | −$225M | −$333M | −$394M | −$349M | −$395M |
| Capital expenditure | $12.8M | $13.6M | $14.0M | $5.8M | $1.1M |
| Free cash flow | −$238M | −$347M | −$408M | −$355M | −$396M |
| FCF margin | −719.4% | −665.5% | −1,124.9% | −612.8% | −585.0% |
| Share count change | 26.6% | 8.6% | 15.3% | 11.4% | 9.6% |
| Debt and strength | |||||
| Cash and short-term investments | $749M | $1.2B | $912M | $602M | $450M |
| Shareholders' equity | $1.0B | $1.2B | $1.1B | $872M | $671M |
| Current ratio | 6.1x | 9.6x | 8.7x | 5.8x | 5.1x |
| Returns and quality | |||||
| Return on equity | −34.2% | −41.7% | −42.1% | −54.0% | −53.5% |
| Return on tangible equity | −25.8% | −38.4% | −45.8% | −59.5% | −61.5% |
| Piotroski F-score | 1 | 3 | 1 | 2 | 2 |
| Altman Z'' | 4.4 | 4.7 | 2.0 | −3.2 | −6.1 |
Insiders bought, 12 months
$1.4M
1 insider
Insiders sold, 12 months
$2.2M
7 insiders
Of sales under plans
56%
$1.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Intellia Therapeutics, Inc. · NTLA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.26 a share, the company is worth $1.5B.
Source: SEC EDGAR XBRL filings (CIK 0001652130). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.